by clearskymd | Sep 28, 2018 | Blog
ClearSky Medical Diagnostics will be heading to Hong Kong in October for the 22nd International Congress of Parkinson’s Disease and Movement Disorders (MDS). The Congress will bring together world-renowned delegates sharing information on neurodegenerative and...
by clearskymd | Sep 28, 2018 | Company News, Parkinson's
Large scale research in China backs up the validity and high accuracy of PD-Monitor for Parkinson’s diagnosis ClearSky’s PD-Monitor can be used to confirm the diagnosis of Parkinson’s in very early stages based on the presence of bradykinesia in the...
by clearskymd | Jul 20, 2018 | Blog
ClearSky Medical Diagnostics is proud to be part of an award-winning team that scooped top prize in the Human-Competitive Awards (Humies) 2018 in Japan. The Humies Awards recognise work that has not just solved some problem via techniques from evolutionary computation...
by clearskymd | Jul 16, 2018 | Company News
Members of the ClearSky team have been selected as finalists in the Human-Competitive Awards (Humies), which take place at GECCO 2018 in Japan this week. The Humies Awards recognise work that has not just solved some problem via techniques from evolutionary...
by clearskymd | Jun 20, 2018 | Company News
ClearSky’s PD-Monitor has been used in a nationwide study to investigate whether statins are effective in slowing the progress of Parkinson’s. Statins, such as Simvastatin, are a group of medicines that are currently prescribed to lower cholesterol in the blood....
by clearskymd | Jun 7, 2018 | Company News
ClearSky’s co-founder and director Professor Stephen Smith was recently awarded a secondment to evaluate the technology for measuring the symptoms of Parkinson’s. Professor Stephen Smith, Deputy Head of the Department of Electronic Engineering at the University of...
by clearskymd | Jun 4, 2018 | Company News
ClearSky Medical Diagnostics is delighted to announce the appointment of two new members of staff – Marta Vallejo and Amir Dehsarvi. Dr Vallejo has joined ClearSky in the newly-formed role of Head of AI and Machine Learning and will be responsible for the development...
by clearskymd | Jun 1, 2018 | Company News
Implementing ClearSky’s LID-Monitor in UK hospitals ‘has the potential to reduce costs to the NHS and increase the quality of life of people with Parkinson’s’… Parkinson’s is a progressive neurological condition – the second most common neurodegenerative disorder...
by clearskymd | May 31, 2018 | Blog
Levodopa is the most effective and commonly used drug for treating Parkinson’s. It is a chemical building-block that your body converts into dopamine. People with Parkinson’s lack enough dopamine because some of the brain cells that make it have died. The loss of...
by clearskymd | Apr 1, 2018 | Company News
The ClearSky China team exhibited at the 2018 Shanghai Ruijin International Forum of Translational Research in Neurodegenerative Disease in March. It was also the second annual meeting of neurodegenerative diseases of The Chinese Neuroscience Society. Around 300...
Recent Comments